Stock Analysis on Net

Cigna Group (NYSE:CI)

Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Cigna Group, consolidated income statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Pharmacy revenues 48,284 45,101 42,036 36,604 34,531 33,964 32,144 33,135 32,762 31,972 30,697 32,328 31,013 30,047 28,025 28,305 27,802 26,564 25,098 25,645 25,987 26,288 25,179
Premiums 11,436 11,454 11,603 11,175 10,998 11,039 11,025 9,547 9,586 10,426 10,356 10,342 10,275 10,323 10,214 10,699 10,682 10,406 10,840 10,005 9,935 9,803 9,971
Fees and other revenues 3,889 3,647 3,326 3,045 3,198 3,305 3,071 2,857 2,728 2,757 2,538 2,638 2,532 2,451 2,341 2,337 2,174 2,072 2,178 2,240 2,285 2,388 2,450
Revenues from external customers 63,609 60,202 56,965 50,824 48,727 48,308 46,240 45,539 45,076 45,155 43,591 45,308 43,820 42,821 40,580 41,341 40,658 39,042 38,116 37,890 38,207 38,479 37,600
Pharmacy and other service costs (47,565) (44,492) (41,431) (35,261) (33,639) (33,442) (31,459) (32,094) (31,777) (31,150) (29,813) (31,247) (30,070) (29,001) (27,235) (27,059) (26,624) (25,611) (24,190) (24,103) (24,552) (24,963) (24,050)
Medical costs and other benefit expenses (9,527) (9,515) (9,440) (9,280) (8,927) (9,034) (9,046) (7,992) (7,754) (8,192) (8,268) (8,743) (8,330) (8,484) (8,005) (8,847) (8,429) (7,112) (8,322) (7,889) (7,734) (7,576) (7,620)
Gross profit 6,517 6,195 6,094 6,283 6,161 5,832 5,735 5,453 5,545 5,813 5,510 5,318 5,420 5,336 5,340 5,435 5,605 6,319 5,604 5,898 5,921 5,940 5,930
Net investment income 85 321 290 290 321 278 277 212 204 325 414 380 468 310 391 371 297 223 353 355 349 340 346
Selling, general and administrative expenses (3,590) (3,684) (3,705) (4,062) (3,788) (3,434) (3,538) (3,483) (3,148) (3,256) (3,299) (3,662) (3,093) (2,996) (3,279) (3,966) (3,301) (3,407) (3,398) (3,957) (3,413) (3,380) (3,303)
Amortization of acquired intangible assets (436) (420) (423) (451) (454) (455) (459) (457) (460) (501) (458) (499) (501) (503) (495) (495) (493) (496) (498) (735) (734) (737) (743)
Income from operations 2,576 2,412 2,256 2,060 2,240 2,221 2,015 1,725 2,141 2,381 2,167 1,537 2,294 2,147 1,957 1,345 2,108 2,639 2,061 1,561 2,123 2,163 2,230
Interest expense and other (376) (375) (322) (360) (365) (363) (358) (324) (304) (301) (299) (293) (303) (298) (314) (337) (336) (374) (391) (391) (411) (428) (452)
Debt extinguishment costs (10) (131) (14) (185) (2)
Gain (loss) on sale of businesses (87) (19) (1,478) (21) (73) 1,735 4,203
Net realized investment gains (losses) (921) (48) (1,836) (34) (14) 26 (56) (81) (95) (319) 68 68 59 1 167 32 38 (88) 93 51 23 10
Income before income taxes 1,192 1,989 79 188 1,840 1,884 1,601 1,328 3,491 1,985 1,549 1,312 2,059 1,898 1,513 5,378 1,804 2,289 1,397 1,261 1,763 1,758 1,788
Income taxes (367) (360) (291) 919 (391) (374) (295) (130) (713) (413) (351) (179) (424) (422) (342) (1,236) (406) (529) (208) (277) (409) (348) (416)
Net income (loss) 825 1,629 (212) 1,107 1,449 1,510 1,306 1,198 2,778 1,572 1,198 1,133 1,635 1,476 1,171 4,142 1,398 1,760 1,189 984 1,354 1,410 1,372
Net income attributable to noncontrolling interests (86) (81) (65) (78) (41) (50) (39) (29) (21) (13) (15) (17) (14) (9) (10) (7) (10) (6) (8) (7) (3) (2) (4)
Shareholders’ net income (loss) 739 1,548 (277) 1,029 1,408 1,460 1,267 1,169 2,757 1,559 1,183 1,116 1,621 1,467 1,161 4,135 1,388 1,754 1,181 977 1,351 1,408 1,368

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Revenues from external customers Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Cigna Group revenues from external customers increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Income from operations The net result for the period of deducting operating expenses from operating revenues. Cigna Group income from operations increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Income before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Cigna Group income before income taxes increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024.
Shareholders’ net income (loss) The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Cigna Group shareholders’ net income (loss) increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024.